Brought to you by 
Gilead and GlobeImmune develop new HBV vaccines; deal ends
18 Nov 2016
Executive Summary
Gilead Sciences Inc. and GlobeImmune Inc. (cancer and infectious disease vaccines) will work together to develop vaccines that can be used with Gilead’s Viread (tenofovir) and other oral chronic hepatitis B virus infection therapeutics.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
- Vaccines
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Contract
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Gilead and GlobeImmune develop new HBV vaccines; deal ends
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice